ARTICLES BY LOUIS

• Exclusive Interview: WuXi AppTec Responds To BIOSECURE Act

  5/13/2024

  Rick Connell, WuXi AppTec’s President, U.S. and Europe, agreed to an exclusive interview with Chief Editor Louis Garguilo to address accusations in the BIOSECURE Act. To understand Connell is to understand the shock at WuXi AppTec – and  among its customers.

• Don't Blame The Molecule; You May Be The Problem

  5/6/2024

  Ali Pashazadeh has been a healthcare investment banker for 20 years, surgeon for 30, and biotech CEO. Today he leads Treehill Partners. “I can explain our logic in two minutes,” he says of his approach to developing drugs, and targeting diseases.

• A Spy At Moderna

  5/1/2024

  Jason Kerr of Moderna is a snoop, a spy, a watcher of all things. More officially, he’s tasked by his employer with monitoring for regulatory changes in the environment. “Some do call it regulatory surveillance,” he says, “Some just regulatory monitoring.” Whichever, you might need to hire a Kerr, too. Here's why.

• Nothing To See Here! Just Big Pharma Investments In China

  4/22/2024

  WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

• CDMOs Pelted By Slings And Arrows

  4/18/2024

  Chief Editor Louis Garguilo thought he was precipitating a frontal assault by canvassing the Outsourced Pharma Editorial Advisory Board with questions such as: When outsourcing development and manufacturing, what are the challenges, and where are your pain points? But before anyone claims “one-sided,” please read on.

• A Good Feeling ($$) About Contract Manufacturing

  4/15/2024

  Occasionally, we look at revenue numbers assigned to the collective activities we focus on at Outsourced Pharma: drug development and manufacturing outsourcing, and working with CDMOs. And we also can provide some pep talks, too.

• You Want To Rein In China? Then Actually Do It

  4/12/2024

  Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.

• Stop Fixating On CDMO Pricing!

  4/8/2024

  You may have an ill-advised idée fixe on the prices your CDMO is charging you. Who says? Among others, members of our Outsourced Pharma Editorial Advisory Board – a practical and practiced assembly of successful outsourcing professionals. And they start with an offensive C-suite.

• From Ally To Adversary: BIO's Swift Rebuke Of WuXi

  4/5/2024

  The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.

• Gene Circuits And Biofabs: Building The Evolution

  4/1/2024

  Can’t find a bio fabrication plant for your gene circuits? Chief Editor Louis Garguilo has located a candidate. It arrives in a for-contract, state-of-the-art capability being carved out by an emerging biopharma. Circuits and biofab described within.